APO Research
Talk to an analyst

APO RESEARCH · REPORT

C-X-C Chemokine Receptor Type 4

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global C-X-C Chemokine Receptor Type 4 Market Outlook and Growth Opportunities 2026

19 December 2025206 pages

Choose your research edition.

Industry ResearchC-X-C Chemokine Receptor Type 4 Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal C-X-C Chemokine Receptor Type 4 Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal C-X-C Chemokine Receptor Type 4 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C-X-C Chemokine Receptor Type 4 Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal C-X-C Chemokine Receptor Type 4 Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global C-X-C Chemokine Receptor Type 4 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for C-X-C Chemokine Receptor Type 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for C-X-C Chemokine Receptor Type 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for C-X-C Chemokine Receptor Type 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the C-X-C Chemokine Receptor Type 4 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the C-X-C Chemokine Receptor Type 4 market include Sanofi, Eli Lilly and Company, X4 Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc., TaiGen Biotechnology Co., Ltd., Polyphor Ltd., Pharis Biotec GmbH, NeED Pharma s.r.l. and GlycoMimetics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global C-X-C Chemokine Receptor Type 4 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of C-X-C Chemokine Receptor Type 4 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents C-X-C Chemokine Receptor Type 4 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global C-X-C Chemokine Receptor Type 4 market.

C-X-C Chemokine Receptor Type 4 Segment by Company

Sanofi

Eli Lilly and Company

X4 Pharmaceuticals, Inc.

Upsher-Smith Laboratories, Inc.

TaiGen Biotechnology Co., Ltd.

Polyphor Ltd.

Pharis Biotec GmbH

NeED Pharma s.r.l.

GlycoMimetics, Inc.

Globavir Biosciences, Inc.

Bristol-Myers Squibb Company

BioLineRx, Ltd.

Biokine Therapeutics Ltd.

Anchor Therapeutics, Inc.

Ambrx, Inc.

AdAlta Pty Ltd.

C-X-C Chemokine Receptor Type 4 Segment by Type

HPH-112

GMI-1359

BL-8040

AM-3114

Others

C-X-C Chemokine Receptor Type 4 Segment by Application

Myocardial Infarction

Renal Cell Carcinoma

Stroke

Liver Cancer

Others

C-X-C Chemokine Receptor Type 4 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global C-X-C Chemokine Receptor Type 4 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the C-X-C Chemokine Receptor Type 4 key companies, revenue, market share, and recent developments.

3. To split the C-X-C Chemokine Receptor Type 4 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions C-X-C Chemokine Receptor Type 4 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify C-X-C Chemokine Receptor Type 4 significant trends, drivers, influence factors in global and regions.

6. To analyze C-X-C Chemokine Receptor Type 4 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-X-C Chemokine Receptor Type 4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C-X-C Chemokine Receptor Type 4 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-X-C Chemokine Receptor Type 4.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global C-X-C Chemokine Receptor Type 4 industry.

Chapter 3: Detailed analysis of C-X-C Chemokine Receptor Type 4 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of C-X-C Chemokine Receptor Type 4 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of C-X-C Chemokine Receptor Type 4 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. C-X-C Chemokine Receptor Type 4 Industry Trends Table 2. C-X-C Chemokine Receptor Type 4 Industry Drivers Table 3. C-X-C Chemokine Receptor Type 4 Industry Opportunities and Challenges Table 4. C-X-C Chemokine Receptor Type 4 Industry Restraints Table 5. Global C-X-C Chemokine Receptor Type 4 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global C-X-C Chemokine Receptor Type 4 Revenue Share by Company (2021-2026) Table 7. Global C-X-C Chemokine Receptor Type 4 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global C-X-C Chemokine Receptor Type 4 Key Company Manufacturing Base & Headquarters Table 9. Global C-X-C Chemokine Receptor Type 4 Company, Product Type & Application Table 10. Global C-X-C Chemokine Receptor Type 4 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global C-X-C Chemokine Receptor Type 4 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of HPH-112 Table 15. Significant Companies of GMI-1359 Table 16. Significant Companies of BL-8040 Table 17. Significant Companies of AM-3114 Table 18. Significant Companies of Others Table 19. Global C-X-C Chemokine Receptor Type 4 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global C-X-C Chemokine Receptor Type 4 Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global C-X-C Chemokine Receptor Type 4 Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Type (2021-2026) Table 23. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Myocardial Infarction Table 25. Significant Companies of Renal Cell Carcinoma Table 26. Significant Companies of Stroke Table 27. Significant Companies of Liver Cancer Table 28. Significant Companies of Others Table 29. Global C-X-C Chemokine Receptor Type 4 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global C-X-C Chemokine Receptor Type 4 Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global C-X-C Chemokine Receptor Type 4 Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Application (2021-2026) Table 33. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Application (2027-2032) Table 34. Global C-X-C Chemokine Receptor Type 4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global C-X-C Chemokine Receptor Type 4 Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Region (2021-2026) Table 37. Global C-X-C Chemokine Receptor Type 4 Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Region (2027-2032) Table 39. Global C-X-C Chemokine Receptor Type 4 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global C-X-C Chemokine Receptor Type 4 Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global C-X-C Chemokine Receptor Type 4 Sales Value Market Share by Country (2021-2026) Table 42. Global C-X-C Chemokine Receptor Type 4 Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global C-X-C Chemokine Receptor Type 4 Sales Value Market Share by Country (2027-2032) Table 44. Sanofi Company Information Table 45. Sanofi Business Overview Table 46. Sanofi C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sanofi C-X-C Chemokine Receptor Type 4 Product Portfolio Table 48. Sanofi Recent Development Table 49. Eli Lilly and Company Company Information Table 50. Eli Lilly and Company Business Overview Table 51. Eli Lilly and Company C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Eli Lilly and Company C-X-C Chemokine Receptor Type 4 Product Portfolio Table 53. Eli Lilly and Company Recent Development Table 54. X4 Pharmaceuticals, Inc. Company Information Table 55. X4 Pharmaceuticals, Inc. Business Overview Table 56. X4 Pharmaceuticals, Inc. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. X4 Pharmaceuticals, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 58. X4 Pharmaceuticals, Inc. Recent Development Table 59. Upsher-Smith Laboratories, Inc. Company Information Table 60. Upsher-Smith Laboratories, Inc. Business Overview Table 61. Upsher-Smith Laboratories, Inc. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Upsher-Smith Laboratories, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 63. Upsher-Smith Laboratories, Inc. Recent Development Table 64. TaiGen Biotechnology Co., Ltd. Company Information Table 65. TaiGen Biotechnology Co., Ltd. Business Overview Table 66. TaiGen Biotechnology Co., Ltd. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. TaiGen Biotechnology Co., Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 68. TaiGen Biotechnology Co., Ltd. Recent Development Table 69. Polyphor Ltd. Company Information Table 70. Polyphor Ltd. Business Overview Table 71. Polyphor Ltd. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Polyphor Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 73. Polyphor Ltd. Recent Development Table 74. Pharis Biotec GmbH Company Information Table 75. Pharis Biotec GmbH Business Overview Table 76. Pharis Biotec GmbH C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pharis Biotec GmbH C-X-C Chemokine Receptor Type 4 Product Portfolio Table 78. Pharis Biotec GmbH Recent Development Table 79. NeED Pharma s.r.l. Company Information Table 80. NeED Pharma s.r.l. Business Overview Table 81. NeED Pharma s.r.l. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. NeED Pharma s.r.l. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 83. NeED Pharma s.r.l. Recent Development Table 84. GlycoMimetics, Inc. Company Information Table 85. GlycoMimetics, Inc. Business Overview Table 86. GlycoMimetics, Inc. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlycoMimetics, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 88. GlycoMimetics, Inc. Recent Development Table 89. Globavir Biosciences, Inc. Company Information Table 90. Globavir Biosciences, Inc. Business Overview Table 91. Globavir Biosciences, Inc. C-X-C Chemokine Receptor Type 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Globavir Biosciences, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 93. Globavir Biosciences, Inc. Recent Development Table 94. Bristol-Myers Squibb Company Company Information Table 95. Bristol-Myers Squibb Company Business Overview Table 96. Bristol-Myers Squibb Company C-X-C Chemokine Receptor Type 4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Bristol-Myers Squibb Company C-X-C Chemokine Receptor Type 4 Product Portfolio Table 98. Bristol-Myers Squibb Company Recent Development Table 99. BioLineRx, Ltd. Company Information Table 100. BioLineRx, Ltd. Business Overview Table 101. BioLineRx, Ltd. C-X-C Chemokine Receptor Type 4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. BioLineRx, Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 103. BioLineRx, Ltd. Recent Development Table 104. Biokine Therapeutics Ltd. Company Information Table 105. Biokine Therapeutics Ltd. Business Overview Table 106. Biokine Therapeutics Ltd. C-X-C Chemokine Receptor Type 4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Biokine Therapeutics Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 108. Biokine Therapeutics Ltd. Recent Development Table 109. Anchor Therapeutics, Inc. Company Information Table 110. Anchor Therapeutics, Inc. Business Overview Table 111. Anchor Therapeutics, Inc. C-X-C Chemokine Receptor Type 4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Anchor Therapeutics, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 113. Anchor Therapeutics, Inc. Recent Development Table 114. Ambrx, Inc. Company Information Table 115. Ambrx, Inc. Business Overview Table 116. Ambrx, Inc. C-X-C Chemokine Receptor Type 4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Ambrx, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 118. Ambrx, Inc. Recent Development Table 119. AdAlta Pty Ltd. Company Information Table 120. AdAlta Pty Ltd. Business Overview Table 121. AdAlta Pty Ltd. C-X-C Chemokine Receptor Type 4 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. AdAlta Pty Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio Table 123. AdAlta Pty Ltd. Recent Development Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. C-X-C Chemokine Receptor Type 4 Product Image Figure 2. Global C-X-C Chemokine Receptor Type 4 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C-X-C Chemokine Receptor Type 4 Market Size (2021-2032) & (US$ Million) Figure 4. Global C-X-C Chemokine Receptor Type 4 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. HPH-112 Image Figure 8. GMI-1359 Image Figure 9. BL-8040 Image Figure 10. AM-3114 Image Figure 11. Others Image Figure 12. Global C-X-C Chemokine Receptor Type 4 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global C-X-C Chemokine Receptor Type 4 Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Type (2021-2032) Figure 15. Myocardial Infarction Image Figure 16. Renal Cell Carcinoma Image Figure 17. Stroke Image Figure 18. Liver Cancer Image Figure 19. Others Image Figure 20. Global C-X-C Chemokine Receptor Type 4 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global C-X-C Chemokine Receptor Type 4 Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Application (2021-2032) Figure 23. Global C-X-C Chemokine Receptor Type 4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032) & (US$ Million) Figure 26. North America C-X-C Chemokine Receptor Type 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032) & (US$ Million) Figure 28. Europe C-X-C Chemokine Receptor Type 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific C-X-C Chemokine Receptor Type 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032) & (US$ Million) Figure 32. South America C-X-C Chemokine Receptor Type 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa C-X-C Chemokine Receptor Type 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • HPH-112
  • GMI-1359
  • BL-8040
  • AM-3114
  • Others
Applications
  • Myocardial Infarction
  • Renal Cell Carcinoma
  • Stroke
  • Liver Cancer
  • Others
Companies covered
  • Sanofi
  • Eli Lilly and Company
  • X4 Pharmaceuticals, Inc.
  • Upsher-Smith Laboratories, Inc.
  • TaiGen Biotechnology Co., Ltd.
  • Polyphor Ltd.
  • Pharis Biotec GmbH
  • NeED Pharma s.r.l.
  • GlycoMimetics, Inc.
  • Globavir Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • BioLineRx, Ltd.
  • Biokine Therapeutics Ltd.
  • Anchor Therapeutics, Inc.
  • Ambrx, Inc.
  • AdAlta Pty Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global C-X-C Chemokine Receptor Type 4 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global C-X-C Chemokine Receptor Type 4 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 C-X-C Chemokine Receptor Type 4 Market Dynamics
  1. 2.1 C-X-C Chemokine Receptor Type 4 Industry Trends
  2. 2.2 C-X-C Chemokine Receptor Type 4 Industry Drivers
  3. 2.3 C-X-C Chemokine Receptor Type 4 Industry Opportunities and Challenges
  4. 2.4 C-X-C Chemokine Receptor Type 4 Industry Restraints
3 C-X-C Chemokine Receptor Type 4 Market by Company
  1. 3.1 Global C-X-C Chemokine Receptor Type 4 Company Revenue Ranking in 2025
  2. 3.2 Global C-X-C Chemokine Receptor Type 4 Revenue by Company (2021-2026)
  3. 3.3 Global C-X-C Chemokine Receptor Type 4 Company Ranking (2024-2026)
  4. 3.4 Global C-X-C Chemokine Receptor Type 4 Company Manufacturing Base and Headquarters
  5. 3.5 Global C-X-C Chemokine Receptor Type 4 Company Product Type and Application
  6. 3.6 Global C-X-C Chemokine Receptor Type 4 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global C-X-C Chemokine Receptor Type 4 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 C-X-C Chemokine Receptor Type 4 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 C-X-C Chemokine Receptor Type 4 Market by Type
  1. 4.1 C-X-C Chemokine Receptor Type 4 Type Introduction
  2. 4.1.1 HPH-112
  3. 4.1.2 GMI-1359
  4. 4.1.3 BL-8040
  5. 4.1.4 AM-3114
  6. 4.1.5 Others
  7. 4.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Type
  8. 4.2.1 Global C-X-C Chemokine Receptor Type 4 Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Type (2021-2032)
  10. 4.2.3 Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Type (2021-2032)
5 C-X-C Chemokine Receptor Type 4 Market by Application
  1. 5.1 C-X-C Chemokine Receptor Type 4 Application Introduction
  2. 5.1.1 Myocardial Infarction
  3. 5.1.2 Renal Cell Carcinoma
  4. 5.1.3 Stroke
  5. 5.1.4 Liver Cancer
  6. 5.1.5 Others
  7. 5.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Application
  8. 5.2.1 Global C-X-C Chemokine Receptor Type 4 Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Application (2021-2032)
  10. 5.2.3 Global C-X-C Chemokine Receptor Type 4 Sales Value Share by Application (2021-2032)
6 C-X-C Chemokine Receptor Type 4 Regional Value Analysis
  1. 6.1 Global C-X-C Chemokine Receptor Type 4 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Region (2021-2032)
  3. 6.2.1 Global C-X-C Chemokine Receptor Type 4 Sales Value by Region: 2021-2026
  4. 6.2.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032)
  7. 6.3.2 North America C-X-C Chemokine Receptor Type 4 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032)
  10. 6.4.2 Europe C-X-C Chemokine Receptor Type 4 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific C-X-C Chemokine Receptor Type 4 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032)
  16. 6.6.2 South America C-X-C Chemokine Receptor Type 4 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa C-X-C Chemokine Receptor Type 4 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa C-X-C Chemokine Receptor Type 4 Sales Value Share by Country, 2025 VS 2032
7 C-X-C Chemokine Receptor Type 4 Country-level Value Analysis
  1. 7.1 Global C-X-C Chemokine Receptor Type 4 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Country (2021-2032)
  3. 7.2.1 Global C-X-C Chemokine Receptor Type 4 Sales Value by Country (2021-2026)
  4. 7.2.2 Global C-X-C Chemokine Receptor Type 4 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt C-X-C Chemokine Receptor Type 4 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt C-X-C Chemokine Receptor Type 4 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt C-X-C Chemokine Receptor Type 4 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi C-X-C Chemokine Receptor Type 4 Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company C-X-C Chemokine Receptor Type 4 Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 X4 Pharmaceuticals, Inc.
  14. 8.3.1 X4 Pharmaceuticals, Inc. Company Information
  15. 8.3.2 X4 Pharmaceuticals, Inc. Business Overview
  16. 8.3.3 X4 Pharmaceuticals, Inc. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 X4 Pharmaceuticals, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
  18. 8.3.5 X4 Pharmaceuticals, Inc. Recent Developments
  19. 8.4 Upsher-Smith Laboratories, Inc.
  20. 8.4.1 Upsher-Smith Laboratories, Inc. Company Information
  21. 8.4.2 Upsher-Smith Laboratories, Inc. Business Overview
  22. 8.4.3 Upsher-Smith Laboratories, Inc. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Upsher-Smith Laboratories, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
  24. 8.4.5 Upsher-Smith Laboratories, Inc. Recent Developments
  25. 8.5 TaiGen Biotechnology Co., Ltd.
  26. 8.5.1 TaiGen Biotechnology Co., Ltd. Company Information
  27. 8.5.2 TaiGen Biotechnology Co., Ltd. Business Overview
  28. 8.5.3 TaiGen Biotechnology Co., Ltd. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 TaiGen Biotechnology Co., Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
  30. 8.5.5 TaiGen Biotechnology Co., Ltd. Recent Developments
  31. 8.6 Polyphor Ltd.
  32. 8.6.1 Polyphor Ltd. Company Information
  33. 8.6.2 Polyphor Ltd. Business Overview
  34. 8.6.3 Polyphor Ltd. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Polyphor Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
  36. 8.6.5 Polyphor Ltd. Recent Developments
  37. 8.7 Pharis Biotec GmbH
  38. 8.7.1 Pharis Biotec GmbH Company Information
  39. 8.7.2 Pharis Biotec GmbH Business Overview
  40. 8.7.3 Pharis Biotec GmbH C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pharis Biotec GmbH C-X-C Chemokine Receptor Type 4 Product Portfolio
  42. 8.7.5 Pharis Biotec GmbH Recent Developments
  43. 8.8 NeED Pharma s.r.l.
  44. 8.8.1 NeED Pharma s.r.l. Company Information
  45. 8.8.2 NeED Pharma s.r.l. Business Overview
  46. 8.8.3 NeED Pharma s.r.l. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NeED Pharma s.r.l. C-X-C Chemokine Receptor Type 4 Product Portfolio
  48. 8.8.5 NeED Pharma s.r.l. Recent Developments
  49. 8.9 GlycoMimetics, Inc.
  50. 8.9.1 GlycoMimetics, Inc. Company Information
  51. 8.9.2 GlycoMimetics, Inc. Business Overview
  52. 8.9.3 GlycoMimetics, Inc. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlycoMimetics, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
  54. 8.9.5 GlycoMimetics, Inc. Recent Developments
  55. 8.10 Globavir Biosciences, Inc.
  56. 8.10.1 Globavir Biosciences, Inc. Company Information
  57. 8.10.2 Globavir Biosciences, Inc. Business Overview
  58. 8.10.3 Globavir Biosciences, Inc. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Globavir Biosciences, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
  60. 8.10.5 Globavir Biosciences, Inc. Recent Developments
  61. 8.11 Bristol-Myers Squibb Company
  62. 8.11.1 Bristol-Myers Squibb Company Company Information
  63. 8.11.2 Bristol-Myers Squibb Company Business Overview
  64. 8.11.3 Bristol-Myers Squibb Company C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Company C-X-C Chemokine Receptor Type 4 Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Company Recent Developments
  67. 8.12 BioLineRx, Ltd.
  68. 8.12.1 BioLineRx, Ltd. Company Information
  69. 8.12.2 BioLineRx, Ltd. Business Overview
  70. 8.12.3 BioLineRx, Ltd. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioLineRx, Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
  72. 8.12.5 BioLineRx, Ltd. Recent Developments
  73. 8.13 Biokine Therapeutics Ltd.
  74. 8.13.1 Biokine Therapeutics Ltd. Company Information
  75. 8.13.2 Biokine Therapeutics Ltd. Business Overview
  76. 8.13.3 Biokine Therapeutics Ltd. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biokine Therapeutics Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
  78. 8.13.5 Biokine Therapeutics Ltd. Recent Developments
  79. 8.14 Anchor Therapeutics, Inc.
  80. 8.14.1 Anchor Therapeutics, Inc. Company Information
  81. 8.14.2 Anchor Therapeutics, Inc. Business Overview
  82. 8.14.3 Anchor Therapeutics, Inc. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Anchor Therapeutics, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
  84. 8.14.5 Anchor Therapeutics, Inc. Recent Developments
  85. 8.15 Ambrx, Inc.
  86. 8.15.1 Ambrx, Inc. Company Information
  87. 8.15.2 Ambrx, Inc. Business Overview
  88. 8.15.3 Ambrx, Inc. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ambrx, Inc. C-X-C Chemokine Receptor Type 4 Product Portfolio
  90. 8.15.5 Ambrx, Inc. Recent Developments
  91. 8.16 AdAlta Pty Ltd.
  92. 8.16.1 AdAlta Pty Ltd. Company Information
  93. 8.16.2 AdAlta Pty Ltd. Business Overview
  94. 8.16.3 AdAlta Pty Ltd. C-X-C Chemokine Receptor Type 4 Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AdAlta Pty Ltd. C-X-C Chemokine Receptor Type 4 Product Portfolio
  96. 8.16.5 AdAlta Pty Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst